Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOVIE metronomic oral vinorelbine + durvalumab/tremelimumab in advanced solid tumours
2024-518151-29-00Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jun 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tremelimumab and vinorelbine in head and neck squamous cell carcinoma (HNSCC), breast cancer, prostate cancer (PCa) and 3 more, sponsored by Unicancer. Primary endpoints: Maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of metronomic oral vinorelbine in combination with durvalumab + tremelimumab and Clinical benefit rate at 24 weeks (CBR24). Started Jun 2018; status: completed.
02
Drugs
durvalumabtremelimumabvinorelbine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)breast cancerprostate cancer (PCa)Cervical Cancer (CC)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-518151-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518151-29-00.